Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 81.08% is in line with its 5-year average of 86.11%, near the low end of its 5-year range (77.27%–108.23%).
0.53% above its 12-month average of 80.65%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 83.68%.
GROSS MARGIN
81.08%
GROSS MARGIN AVG TTM
80.65%
GROSS MARGIN AVG 3Y
83.30%
GROSS MARGIN AVG 5Y
86.11%
GROSS MARGIN AVG 10Y
88.34%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.53%
CURRENT VS 3Y AVG
-2.67%
CURRENT VS 5Y AVG
-5.84%
CURRENT VS 10Y AVG
-8.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 696 covered companies
CURRENT VS SECTOR MEDIAN
+100.79%
vs the sector median at left
Market Cap
$103.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$103.60M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
5.83%
5Y Avg
8.02%
Market Cap
$105.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$105.29M
Gross Margin
71.67%
TTM Avg
77.09%
3Y Avg
79.04%
5Y Avg
77.65%
Market Cap
$97.81M
Gross Margin
94.58%
TTM Avg
46.31%
3Y Avg
73.16%
5Y Avg
65.44%
Market Cap
$110.33M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Joint Corp. (JYNT) | $103.21M | 81.08% | 80.65% | 83.30% | 86.11% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anixa Biosciences, Inc. (ANIX)vs › | $103.60M | 0.00% | 0.00% | 5.83% | 8.02% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $105.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Definitive Healthcare Corp. (DH)vs › | $105.29M | 71.67% | 77.09% | 79.04% | 77.65% |
| Korro Bio, Inc. (KRRO)vs › | $98.69M | 33.04% | 66.52% | 33.26% | 38.13% |
| PolyPid Ltd. (PYPD)vs › | $98.56M | 0.00% | 0.00% | 0.00% | 0.00% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.81M | 94.58% | 46.31% | 73.16% | 65.44% |
| Apyx Medical Corporation (APYX)vs › | $110.33M | 33.94% | 48.53% | 56.75% | 59.91% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.48M | 83.37% | 83.81% | 82.64% | 80.50% |
Gross Margin
81.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 83.68% |
| 2026-03-31 | 78.95% |
| 2025-12-31 | 81.41% |
| 2025-09-30 | 80.11% |
| 2025-06-30 | 79.11% |
| 2025-03-31 | 77.27% |
| 2024-12-31 | 108.23% |
| 2024-09-30 | 90.65% |
| 2024-06-30 | 77.70% |
| 2024-03-31 | 77.80% |
| 2023-12-31 | 90.62% |
| 2023-09-30 | 91.16% |
| 2023-06-30 | 91.14% |
| 2023-03-31 | 91.26% |
| 2022-12-31 | 90.65% |
| 2022-09-30 | 91.16% |
| 2022-06-30 | 90.93% |
| 2022-03-31 | 90.51% |
| 2021-12-31 | 89.10% |
| 2021-09-30 | 89.04% |
| 2021-06-30 | 89.92% |
| 2021-03-31 | 89.94% |
| 2020-12-31 | 88.61% |
| 2020-09-30 | 88.89% |
| 2020-06-30 | 89.14% |
| 2020-03-31 | 89.11% |
| 2019-12-31 | 88.22% |
| 2019-09-30 | 88.79% |
| 2019-06-30 | 88.37% |
| 2019-03-31 | 88.71% |
| 2018-12-31 | 86.75% |
| 2018-09-30 | 86.55% |
| 2018-06-30 | 86.08% |
| 2018-03-31 | 86.30% |
| 2017-12-31 | 85.85% |
| 2017-09-30 | 87.49% |
| 2017-06-30 | 87.19% |
| 2017-03-31 | 86.92% |
| 2016-12-31 | 86.97% |
| 2016-09-30 | 86.94% |
| 2016-06-30 | 85.37% |
| 2016-03-31 | 82.65% |
| 2015-12-31 | 80.40% |
| 2015-09-30 | 81.98% |
| 2015-06-30 | 76.89% |
| 2015-03-31 | 78.26% |
| 2014-12-31 | 71.98% |
| 2014-09-30 | 67.75% |
| 2014-06-30 | 68.00% |
| 2014-03-31 | 64.93% |
| 2013-12-31 | 68.97% |
| 2013-09-30 | 66.95% |
